Livongo Health, Inc. develops and operates a consumer digital health platform that provides smart, cellular-connected devices, supplies, informed coaching, data science-enabled insights and facilitates access to medications across multiple chronic conditions. It focuses on diabetes, hypertension, weight management, diabetes prevention, and behavioral health. The company was founded by Kimon Angelides and Glen E. Tullman on October 16, 2008 and is headquartered in Mountain View, CA.
The ‘M-Health Application Market’ study added by Reports web, exhibits a comprehensive analysis of the growth trends present in the global business scenario. The study further presents conclusive data referring to the commercialization aspects, industry size and profit estimation of
Amwell (AMWL) is an interesting telehealth company which shows impressive growth rates which approximate 100% as the result of Covid-19. Telehealth is very hot space yet unlike some industry leaders the pre-Covid-19 growth was not so impressive to me, certainly in combination with sizable losses. For this reason shares probably...
The Value Investor on Seeking Alpha | September 21, 2020
Livongo Health, Inc. (LVGO) Morgan Stanley 18th Annual Global Healthcare Conference Transcript September 16, 2020 9:30 AM ET Executives Jason Gorevic - Chief Executive Officer, Teladoc Health, Inc. Mala Murthy - Chief Financial Officer, Teladoc Health, Inc. Glen Tullman - Executive Chairman and Founder Dr. Jenny Schneider - President Analysts...
SA Transcripts on Seeking Alpha | September 16, 2020
Teladoc Health Inc’s (NYSE: TDOC ) pro-forma revenue growth and synergy targets appear achievable, according to Credit Suisse. The Teladoc Health Analyst: Jailendra Singh upgraded Teladoc Health from Neutral to Outperform with a price target lifted from $225 to $249. The Teladoc Health Takeaways: The company formed by the merger of Teladoc Health and Livongo Health Inc (NASDAQ: LVGO ) could generate annual revenue of around $5 billion, with annual EBITDA of about $1.1 billion in 2025, Singh said in the upgrade note. The analyst named seven factors that are driving the upgrade: The combination of Teladoc and Livongo creates a … Full story available on Benzinga.com